Under the Quick & Clean (Q&C) Plan, Analyst Research Laboratories enables early-stage Israeli life-science companies to gain access to state of the art equipment and staff. Thus, even feasibility studies can be performed on qualified and highly reliable equipment with highly-trained staff, enabling companies to make more reliable Go/No Go decisions.

Frequently, young start-up companies at their early proof-of-concept stages that have not yet secured sufficient funds, cannot afford to subcontract their projects to high-end laboratories. Thus, decisions that are critical for the company’s early product development may be based on data generated from instruments that are not qualified and maintained at the highest level and staff that is not trained to perform work at regulatory-level standards.

Under the Quick & Clean Plan initiated by Analyst, such companies will be provided with a significant discount. This will enable them to perform their analytical and bioanalytical feasibility tests at a world-class laboratory, enjoying the support and knowledge of an experienced team with decades of experience.

Dr. Vivi Ziv, Analyst’s CEO explained: “We have witnessed first-hand, companies that due to lack of funds, chose to perform their initial analytical and bioanalytical work in labs that do not necessarily comply with the highest standards. These companies then came to us for the next steps of development and unfortunately, we discovered that the work previously performed and on which they based their decisions, was not reliable. As a result, these companies wasted a lot of time and money and at the best scenario – had to repeat the work. Unfortunately, some of these companies ceased to exist due to lack of additional funds. We felt that it was our obligation to support the young Israeli life-science start-up industry and devised the Q&C plan. We called it Quick & Clean because Analyst does not know how to work “dirty”, said Dr. Ziv with a smile.

Early-stage Israeli start-ups in the field of pharma, biotech, medical device and medical cannabis, are invited to contact Dr. Ziv at vivi@analyst-labs.com and explore their eligibility to participate in the unique Q&C Plan

About Analyst

Analyst Research Laboratories is a GMP, GLP and GCLP accredited, FDA  Analytical Chemistry Contract Laboratory. The 1,000sqm modern lab that was founded more than 20 years ago, specializes in all aspects of analysis of pharmaceuticals, providing a multitude of Analytical & Bioanalytical services to the pharmaceutical, medical cannabis, biotech and medical device industries, complying with the strictest demands of regulatory authorities in the USA, Europe and Asia (FDA, EPA, ICH, USP and OECD). Please find further information at https://www.analyst-labs.com

Über die Tentamus Group GmbH

Tentamus Group GmbH was founded in 2011. Tentamus is a global product and safety group with a core presence in Europe, UK, Israel, China, Japan, India and the USA. Accredited and licensed Tentamus Group tests, audits and consults on all products involving the human body (food & feed, pharmaceuticals & medical, agrosciences, cosmetics, agriculture & environment and nutraceutical & supplements). Tentamus Group is represented in over 70 locations worldwide. More than 3,000 highly-trained staff members work in over 3 million square feet of laboratory and office spaces. For further information please visit www.tentamus.com.

Firmenkontakt und Herausgeber der Meldung:

Tentamus Group GmbH
An der Industriebahn 26
13088 Berlin
Telefon: +49 (30) 206038-230
Telefax: +49 (30) 206038-190
http://www.tentamus.com

Ansprechpartner:
Dr. Vivi Ziv
CEO Analyst Research Laboratories
E-Mail: vivi@analyst-labs.com
Für die oben stehende Story ist allein der jeweils angegebene Herausgeber (siehe Firmenkontakt oben) verantwortlich. Dieser ist in der Regel auch Urheber des Pressetextes, sowie der angehängten Bild-, Ton-, Video-, Medien- und Informationsmaterialien. Die United News Network GmbH übernimmt keine Haftung für die Korrektheit oder Vollständigkeit der dargestellten Meldung. Auch bei Übertragungsfehlern oder anderen Störungen haftet sie nur im Fall von Vorsatz oder grober Fahrlässigkeit. Die Nutzung von hier archivierten Informationen zur Eigeninformation und redaktionellen Weiterverarbeitung ist in der Regel kostenfrei. Bitte klären Sie vor einer Weiterverwendung urheberrechtliche Fragen mit dem angegebenen Herausgeber. Eine systematische Speicherung dieser Daten sowie die Verwendung auch von Teilen dieses Datenbankwerks sind nur mit schriftlicher Genehmigung durch die United News Network GmbH gestattet.

counterpixel